A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

Inclusion Criteria

• •Study participant must have a diagnosis of moderate to severe plaque psoriasis (PSO) for ≥3 months and:
• •1. Body Surface Area (BSA) affected by psoriasis ≥10 %
• •2. Physician's Global Assessment (PGA) score ≥3 (on a scale from 0 to 4)
• •3. Psoriasis Area and Severity Index (PASI) score is ≥12 or
• •4. PASI score is ≥10 and \<12 with at least one of the following:
• •\>Clinically relevant facial or scalp involvement
• •\>Clinically relevant genital involvement
• •\>Clinically relevant palm and sole involvement
• •\>Clinically relevant axillary involvement Study participants aged ≥12 years may alternatively have a diagnosis of moderate to severe mixed guttate/plaque PSO with \>50 % to \<80 % guttate lesions for ≥3 months, and must meet the same criteria listed above
• •Study participant must be a candidate for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy